Ascletis Pharma Inc.

Investors

Financials & Filing

2025

2024

2023

2022

2021

2020

2019

2018

Next Day Disclosure Returns - Share Buyback
2021-11-11
Voluntary Announcement - Ascletis Announces Approval of Phase II Clinical Trial of ASC22 (Envafolimab) by China NMPA for Immune Restoration/Functional Cure of HIV-1 Infected Patients
2021-11-10
Next Day Disclosure Returns - Share Buyback
2021-11-09
Voluntary Announcement - Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study
2021-11-09
Next Day Disclosure Returns - Share Buyback
2021-11-08
Announcement - Inside Information - Exclusive and Worldwide License Agreement outside Greater China with Suzhou Alphamab for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases
2021-11-08
Next Day Disclosure Returns - Share Buyback
2021-11-05
Next Day Disclosure Returns - Share Buyback
2021-11-04
Next Day Disclosure Returns - Share Buyback
2021-11-03
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
2021-11-03

5

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1